With NHS budgets under pressure and medicine prices inexorably going up, something had to give.
Nevertheless, the decision by some of the world’s largest pharmaceutical firms this summer to challenge public sector powers to limit drug bills in the High Court still raised eyebrows.
The action brought by trade body the Association of the British Pharmaceutical Industry (ABPI) divided the sector, with Britain’s two largest drug makers, FTSE 100 giants GlaxoSmithKline and AstraZeneca, distancing themselves from a move driven by overseas conglomerates.
Read more at The Telegraph